Presidents: Giuseppe Curigliano and Paolo Marchetti
28th – 29th April 2023
Villa Aurelia – Largo di Porta San Pancrazio, 2 – Rome


video a cura di Oreste Fiorenza

Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this.
Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patient-sized medical intervention. Personalized medicine promoters usually highlight its potential to combine a more effective health-care with costs containment, according to the following rules:

monitoring of disease risks and more effective prevention;
• early intervention;
• selection of optimal therapy;
• reduction of trial-and-error prescribing and reduction of adverse drug reactions; • exclusion of unnecessary drugs;
• therapeutic drug monitoring and disease progression/remission monitoring;
• increased patient compliance with therapy.

But, despite expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country. Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.
The aim of the meeting, where we are expecting about 100/120 participants from Italy and Europe, is to discuss with principal key opinion leader about the future prospective of precision medicine and precision oncology and the application in the real world.